Patent Issued for Antibodies recognizing tau (USPTO 11926659).
In: Immunotherapy Weekly, 2024-04-02, S. 2679-2679
serialPeriodical
Zugriff:
Prothena Biosciences Limited has been issued a patent for antibodies that specifically bind to human tau, a protein associated with neurodegenerative diseases such as Alzheimer's. The patent describes the amino acid sequences of the antibodies and their potential applications in inhibiting or reducing tau aggregation, treating tau-related diseases, and measuring treatment efficacy. The invention provides a potential avenue for developing therapies for neurodegenerative diseases characterized by tau pathology. [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Antibodies recognizing tau (USPTO 11926659).
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2024-04-02, S. 2679-2679 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Schlagwort: |
|
Sonstiges: |
|